A single centre retrospective study of the long-term real-world body weight responses to liraglutide or bariatric surgery in adolescents with obesity

Q2 Medicine

Obesity Medicine Pub Date : 2026-03-01 Epub Date: 2026-01-27 DOI:10.1016/j.obmed.2026.100684

Tariq Chukir , Aya Khalil , Noor Suleiman , Odette Chagoury , Shahrad Taheri

{"title":"A single centre retrospective study of the long-term real-world body weight responses to liraglutide or bariatric surgery in adolescents with obesity","authors":"Tariq Chukir , Aya Khalil , Noor Suleiman , Odette Chagoury , Shahrad Taheri","doi":"10.1016/j.obmed.2026.100684","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to describe weight and metabolic outcomes beyond 2 years in adolescents treated with liraglutide or bariatric surgery.</div></div><div><h3>Methods</h3><div>This retrospective study included adolescents aged 12–17 years with obesity who were prescribed liraglutide or underwent bariatric surgery at the Qatar Metabolic Institute between 2017 and 2022. Outcomes included changes in hemoglobin A1C, blood pressure, cholesterol and percentage change in body mass index (BMI).</div></div><div><h3>Results</h3><div>Long-term data were available for 42 liraglutide-treated and 48 surgically-treated adolescents. The mean age was 15.6 ± 1.5 years in the liraglutide group and 15.3 ± 1.5 years in the surgery group, with baseline BMI values of 44.3 ± 7.6 and 47.3 ± 7.4 kg/m<sup>2</sup>, respectively. Adolescents treated with liraglutide achieved a nadir BMI reduction of −6.4 %[IQR–13.7,–2.2], which attenuated to a final reduction of −5.0 ± 16.7 % after 4.3 years. The most common reasons for non-continuous use were personal choice(28 %) and gastrointestinal side effects(20%). Adolescents who underwent bariatric surgery achieved a substantial nadir BMI reduction of 24.1 ± 16.8 %, which was sustained over time, with a final mean BMI reduction of 24.7 ± 17.1 % after approximately 4.6 years of follow-up. Both liraglutide treatment and bariatric surgery were associated with significant improvement in cardiometabolic risk factors.</div></div><div><h3>Conclusion</h3><div>This is the first study to report outcomes with liraglutide use in adolescents with obesity extending to nearly 5 years. Our findings provide timely and practical insights into the long-term outcomes with liraglutide in the adolescent population.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"60 ","pages":"Article 100684"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451847626000023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

This study aims to describe weight and metabolic outcomes beyond 2 years in adolescents treated with liraglutide or bariatric surgery.

Methods

This retrospective study included adolescents aged 12–17 years with obesity who were prescribed liraglutide or underwent bariatric surgery at the Qatar Metabolic Institute between 2017 and 2022. Outcomes included changes in hemoglobin A1C, blood pressure, cholesterol and percentage change in body mass index (BMI).

Results

Long-term data were available for 42 liraglutide-treated and 48 surgically-treated adolescents. The mean age was 15.6 ± 1.5 years in the liraglutide group and 15.3 ± 1.5 years in the surgery group, with baseline BMI values of 44.3 ± 7.6 and 47.3 ± 7.4 kg/m², respectively. Adolescents treated with liraglutide achieved a nadir BMI reduction of −6.4 %[IQR–13.7,–2.2], which attenuated to a final reduction of −5.0 ± 16.7 % after 4.3 years. The most common reasons for non-continuous use were personal choice(28 %) and gastrointestinal side effects(20%). Adolescents who underwent bariatric surgery achieved a substantial nadir BMI reduction of 24.1 ± 16.8 %, which was sustained over time, with a final mean BMI reduction of 24.7 ± 17.1 % after approximately 4.6 years of follow-up. Both liraglutide treatment and bariatric surgery were associated with significant improvement in cardiometabolic risk factors.

Conclusion

This is the first study to report outcomes with liraglutide use in adolescents with obesity extending to nearly 5 years. Our findings provide timely and practical insights into the long-term outcomes with liraglutide in the adolescent population.

查看原文本刊更多论文

对肥胖青少年利拉鲁肽或减肥手术的长期真实体重反应的单中心回顾性研究

目的：本研究旨在描述接受利拉鲁肽或减肥手术治疗的青少年2年后的体重和代谢结果。方法本回顾性研究纳入了2017年至2022年在卡塔尔代谢研究所服用利拉鲁肽或接受减肥手术的12-17岁肥胖青少年。结果包括血红蛋白A1C、血压、胆固醇和身体质量指数（BMI）百分比变化。结果42例利拉鲁肽治疗青少年和48例手术治疗青少年的长期数据可用。利拉鲁肽组平均年龄15.6±1.5岁，手术组平均年龄15.3±1.5岁，基线BMI分别为44.3±7.6和47.3±7.4 kg/m2。接受利拉鲁肽治疗的青少年BMI最低下降幅度为- 6.4% [IQR-13.7, -2.2]， 4.3年后最终下降至- 5.0±16.7%。不持续使用的最常见原因是个人选择（28%）和胃肠道副作用（20%）。接受减肥手术的青少年BMI下降了24.1±16.8%，并持续了一段时间，在大约4.6年的随访后，最终平均BMI下降了24.7±17.1%。利拉鲁肽治疗和减肥手术均与心脏代谢危险因素的显著改善相关。结论：这是第一个报告利拉鲁肽用于肥胖青少年近5年的结果的研究。我们的研究结果为利拉鲁肽在青少年人群中的长期疗效提供了及时和实用的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Medicine Medicine-Public Health, Environmental and Occupational Health

CiteScore

5.50

自引率

0.00%

发文量

审稿时长

40 days

期刊介绍： The official journal of the Shanghai Diabetes Institute Obesity is a disease of increasing global prevalence with serious effects on both the individual and society. Obesity Medicine focusses on health and disease, relating to the very broad spectrum of research in and impacting on humans. It is an interdisciplinary journal that addresses mechanisms of disease, epidemiology and co-morbidities. Obesity Medicine encompasses medical, societal, socioeconomic as well as preventive aspects of obesity and is aimed at researchers, practitioners and educators alike.